Division of Cardiac Surgery, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
J Thorac Cardiovasc Surg. 2010 Jul;140(1):196-202. doi: 10.1016/j.jtcvs.2009.07.081. Epub 2010 Feb 1.
Transapical aortic valve implantation is a recent therapeutic advance for aortic valvular disease. We sought to identify complications--and the relevant technical and management considerations--from our learning curve with this procedure.
We retrospectively reviewed perioperative complications during the first 60 transapical aortic valve implantations at a single institution, performed under compassionate release for patients who were candidates neither for conventional aortic valve replacement nor for transfemoral aortic valve implantation. Access was through a small left anterolateral thoracotomy. Particular attention was paid to securing the apical access site. Rapid ventricular pacing to reduce cardiac forward flow was used during balloon valvuloplasty and valve deployment. Careful positioning was guided by echocardiography and fluoroscopy.
This was a select, high-risk (mean Society of Thoracic Surgeons score, 12.3% +/- 7.8% mortality) cohort. Mean age was 81.1 +/- 7.8 years. Technical success was achieved in 59 (98.3%) cases. One valve was malpositioned too far toward the ventricle, necessitating that a second device be implanted within it. In-hospital, 30-day mortality was 18.3% (11 deaths) overall, decreasing from 33.3% in the first 15 patients to 13.3% in the subsequent 45 patients. The only intraoperative death probably resulted from left main ostial obstruction by extensively calcified aortic cusps. Significant left ventricular apical bleeding occurred in 3 (5.0%) patients. Other complications included stroke in 2 (3.3%) patients and permanent atrioventricular block in 3 (5.0%). There were 4 (6.6%) cases of late pseudoaneurysm of the left ventricular apical access site.
Important lessons have been learned from our early experience with transapical aortic valve implantation, and these may guide others as this technology is adopted more broadly.
经心尖主动脉瓣植入术是治疗主动脉瓣疾病的一种新的治疗方法。我们试图从我们使用这种方法的学习曲线上确定并发症——以及相关的技术和管理考虑因素。
我们回顾性分析了一家机构 60 例经心尖主动脉瓣植入术的围手术期并发症,这些患者是传统主动脉瓣置换术和经股动脉主动脉瓣植入术的候选者。手术入路为小左前外侧开胸术。特别注意确保心尖部进入点的安全。球囊瓣膜成形术和瓣膜植入过程中采用快速心室起搏以减少心脏前向血流。通过超声心动图和荧光透视术指导仔细定位。
这是一个选择的高危(平均胸外科医师学会评分 12.3%±7.8%死亡率)队列。平均年龄为 81.1±7.8 岁。59 例(98.3%)手术技术成功。一个瓣膜放置得离心室太远,需要在其内部植入第二个装置。总的院内 30 天死亡率为 18.3%(11 例死亡),从前 15 例的 33.3%降至随后 45 例的 13.3%。唯一的术中死亡可能是由于主动脉瓣广泛钙化导致左主干开口阻塞所致。3 例(5.0%)患者出现明显的左心室心尖部出血。其他并发症包括 2 例(3.3%)脑卒中患者和 3 例(5.0%)永久性房室传导阻滞。4 例(6.6%)患者出现左心室心尖部入口假性动脉瘤。
从我们早期经心尖主动脉瓣植入术的经验中吸取了重要教训,这些经验可能会指导其他人更广泛地采用这项技术。